NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · MID CAP
Agenus Inc. AGEN
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$114.2M
▲ 10.4% vs FY2024
EPS · FY25
$0.00
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
-2.7%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 114.2M
Revenue, FY2025 · full 17-year series below
Revenue
Net income
The company lost 3 cents on every revenue dollar this year.
Per share
USD 0.00
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin-17.7%
Net margin-2.7%
Return on assets-1.4%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+5.3% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+5.2%
+5.3%
+16.5%
+26.5%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.04B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 226.8M
total assets, end of FY2025
Total assetsUSD 226.8M
EquityUSD -271.1M
CashUSD 3.0M
Gross debtUSD 44.7M
Net debtUSD 41.7M
Current ratio0.41×
Net debt stands at -15% of equity.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.1
0.1
0.2
0.1
0.3
0.1
0.2
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.1
−0.2
−0.2
0.0
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.1
−0.1
−0.2
0.0
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
·
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
·
·
Net income $B
−0.0
−0.2
−0.3
−0.2
−0.0
−0.2
−0.1
−0.2
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
0.00
−10.59
−13.75
−15.64
−0.11
−1.05
−0.80
−1.44
−1.23
−1.46
−1.13
−0.71
−1.12
−0.51
−1.21
−1.41
−2.36
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
·
·
·
·
·
·
·
·
·
−803.7
−187.5
−458.4
·
·
·
·
·
Shares out B
0.04
0.02
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
44 of 44
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed